




# PharmacoGx: Analysis of High Throughput Pharmacogenomics Studies

---


**Petr Smirnov**

Benjamin Haibe-Kains Lab  
Department of Medical Biophysics,  
University of Toronto &  
Princess Margaret Cancer Centre  
University Health Network

## Large panel of cancer cell lines




## Drug sensitivity screening




## Response biomarker discovery


## Comprehensive molecular profiling



## Large panel of cancer cell lines



## Drug sensitivity screening




Noise!

**Y**

||

## Response biomarker discovery

## Comprehensive molecular profiling



$f(X)$

↑

**X**

Noise!

# Pharmacogenomic datasets must be curated

(Meta)data is scattered across data portals and journal websites

Mismatched Identifiers

→ Tedious process of curation and annotation



# Pharmacogenomic datasets must be curated

(Meta)data is scattered across data portals and journal websites



Mismatched Identifiers


→ Tedious process of curation and annotation

Develop **PharmacoGx** to empower data use for:


→ Hypothesis generation and validation

→ Comparative and integrative studies


→ Method development for Biomarker Discovery and Predictive Oncology



# PharmacoGx





$$Y = f(X) \leftarrow X$$



**Per Drug – Cell Pair**







# Univariate Biomarker Discovery

$$Y = \beta_0 + \beta_i G_i + \beta_t T + \beta_b B$$

Y = AAC /IC50


G = Molecular Feature

T = Tissue of Origin

B = Batch

Top molecular features associated with response to AZD6244

Feature Type	Gene ▲	Dataset ▲	Stat ▲	Standardized Coefficient ▲	Nominal ANOVA p-value ▼
mRNA	SPRY2	CCL	AAC	0.42	2e-18
mRNA	LYZ	CCL	AAC	0.38	8e-17
mRNA	SPRY2	FIMM	AAC	0.29	3e-14
mRNA	ZFP36L2	FIMM	AAC	0.27	6e-13



# Next Steps



# Next Steps

Integrate with standard  
Bioconductor data objects


→ SummarizedExperiment &  
MultiAssayExperiment

# Next Steps

Integrate with standard  
Bioconductor data objects

→ SummarizedExperiment &  
MultiAssayExperiment

Drug Combinations



# Next Steps


Integrate with standard  
Bioconductor data objects

→ SummarizedExperiment &  
MultiAssayExperiment

Drug Combinations

Time Dimension

→ IncuCyte





# PHARMACODB

MINE MULTIPLE CANCER PHARMACOGENOMIC DATASETS

Tissue (eg. 'endometrium')



**Search, Visualize, Export**

<https://pharmacodb.pmgenomics.ca>

# Acknowledgements

## BHK lab

### *Princess Margaret Cancer Centre*

- Zhaleh Safikhani → Heather Selby
- Nehme El-Hachem → Rene Quevedo
- Deena Gendoo → Laleh Ghoraie
- Ali Madani → Mark Freeman
- Arvind Mer → Fupan Yao

## External collaborators

- John Quackenbush
- Christos Hatzis
- Christopher Mason
- Leming Shi
- Anna Goldenberg
- Nicolai Juul-Birkbak
- Andrew Beck
- Hugo Aerts

## Collaborators

- Mathieu Lupien
- Trevor Pugh
- Linda Penn
- Lillian Siu
- David Cescon
- Ming-Sound Tsao
- Fei-Fei Liu
- Scott Bratman
- Carl Virtanen
- ...



Canadian  
Cancer  
Society



# Thank you!

**PharmacoGx:**

*<https://bioconductor.org/packages/release/bioc/html/PharmacoGx.html>*

**PharmacoDB:**

*<http://pharmacodb.pmgenomics.ca>*

**Github:**

*<https://github.com/bhklab>*

